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Targeting of nonlipidated, aggregated apoE with
antibodies inhibits amyloid accumulation
Fan Liao,1 Aimin Li,1 Monica Xiong,1 Nga Bien-Ly,2 Hong Jiang,1 Yin Zhang,2 Mary Beth Finn,1 Rosa Hoyle,1 Jennifer Keyser,1
Katheryn B. Lefton,1 Grace O. Robinson,1 Javier Remolina Serrano,1 Adam P. Silverman,2 Jing L. Guo,2 Jennifer Getz,2 Kirk Henne,2
Cheryl E.G. Leyns,1 Gilbert Gallardo,1 Jason D. Ulrich,1 Patrick M. Sullivan,3 Eli Paul Lerner,4 Eloise Hudry,4 Zachary K. Sweeney,2
Mark S. Dennis,2 Bradley T. Hyman,4 Ryan J. Watts,2 and David M. Holtzman1
1

Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri,

USA. 2Denali Therapeutics Inc., South San Francisco, California, USA. 3Department of Medicine, Duke University, Durham, North Carolina, USA. 4MassGeneral Institute for Neurodegenerative Disease,
Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

The apolipoprotein E E4 allele of the APOE gene is the strongest genetic factor for late-onset Alzheimer disease (LOAD). There
is compelling evidence that apoE influences Alzheimer disease (AD) in large part by affecting amyloid ȕ (Aȕ) aggregation and
clearance; however, the molecular mechanism underlying these findings remains largely unknown. Herein, we tested whether
anti–human apoE antibodies can decrease Aȕ pathology in mice producing both human Aȕ and apoE4, and investigated the
mechanism underlying these effects. We utilized APPPS1-21 mice crossed to apoE4-knockin mice expressing human apoE4
(APPPS1-21/APOE4). We discovered an anti–human apoE antibody, anti–human apoE 4 (HAE-4), that specifically recognizes
human apoE4 and apoE3 and preferentially binds nonlipidated, aggregated apoE over the lipidated apoE found in circulation.
HAE-4 also binds to apoE in amyloid plaques in unfixed brain sections and in living APPPS1-21/APOE4 mice. When delivered
centrally or by peripheral injection, HAE-4 reduced Aȕ deposition in APPPS1-21/APOE4 mice. Using adeno-associated
virus to express 2 different full-length anti–apoE antibodies in the brain, we found that HAE antibodies decreased amyloid
accumulation, which was dependent on FcȖ receptor function. These data support the hypothesis that a primary mechanism
for apoE-mediated plaque formation may be a result of apoE aggregation, as preferentially targeting apoE aggregates with
therapeutic antibodies reduces Aȕ pathology and may represent a selective approach to treat AD.

Introduction
Alzheimer disease (AD) is the most common form of dementia and
it affects more than 5 million people in the United States (www.alz.
org). Compelling evidence has shown that amyloid ȕ (Aȕ) plays a
key role in the pathogenesis of AD (1, 2). In autosomal dominant
AD, missense mutations in amyloid precursor protein (APP) or
components of the Ȗ- secretase complex presenilin 1 (PS1) or presenilin 2 (PS2) result in early onset amyloid deposition in the brain
due to a relative increase in production of longer Aȕ species such
as Aȕ42, an increase in all Aȕ species, or an alteration of Aȕ aggregation propensity and clearance (3). Also, a protective mutation in
AD was recently described near the N-terminus of the ȕ secretase
site in APP that results in decreased Aȕ production (4).
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The majority of AD cases are known as late-onset AD (LOAD),
which clinically begins after the age of 65. The apolipoprotein E
(APOE) gene is the strongest genetic risk factor for LOAD. In
humans, the 3 common isoforms of apoE — E2, E3, and E4 — are
encoded by a 299 amino acid protein. Compared with the most
common form of apoE, apoE3 (Cys112, Arg158), each allele of
apoE4 (Arg112, Arg158) strongly increase the risk for AD (~3.7-fold
for one E4 allele and ~12-fold for 2 E4 alleles relative to the E3/
E3 genotype); in contrast, apoE2 (Cys112, Cys158) is protective for
AD (5, 6). How apoE impacts AD pathogenesis is not entirely clear;
however, evidence shows that apoE influences Aȕ aggregation and
clearance (7) and is also found in amyloid plaques (8, 9).
Previously, our group has shown that passive immunotherapy using HJ6.3, an antibody targeting endogenous murine
apoE, strongly suppresses Aȕ pathology in the APPswe/PS1ǻE9
mouse brain when treatment is started prior to plaque onset
(10). When administered after plaque onset, HJ6.3 reduced
brain Aȕ plaque load, restored resting-state functional connectivity, and mildly improved spatial performance in the water
maze (11). However, in order to further explore whether such
an approach could potentially translate into an immunotherapy for humans, studies with apoE antibodies targeting human
apoE in animals expressing human Aȕ and apoE are critical. It
is also important to understand the mechanism(s) underlying
the therapeutic effects.
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Figure 1. Characterization of HAE series anti–apoE
antibodies. (A–D) Antibody binding to plates coated
with recombinant apoE2, apoE3, or apoE4. Serially
titrated HAE antibodies were incubated and binding
was detected with HRP anti–mouse IgG antibody.
(E–G) SPR was used to detect 3-fold serially diluted
apoE antibody (starting at 100 nM for HAE-2 and 1000
nM for HAE-1 and HAE-4) binding to biotinylated
recombinant apoE4 captured on a streptavidin chip.
Samples were injected at a flow rate of 30 ȝl/min.

In the present study, we tested the effects of anti–human apoE
(HAE) antibodies, a new series of apoE antibodies targeting human
apoE, on Aȕ pathology in APPPS1-21/APOE4-knockin (KI) mice.
These mice were generated by crossing human apoE4-KI mice
expressing human apoE4 under the control of endogenous murine
apoE regulatory elements (APOE4) (12) to line APPPS1-21 (13). We
found that HAE-4, an antibody specific for apoE3 and apoE4, was
able to reduce Aȕ deposition when infused directly into the brain,
delivered by i.p. injection starting at the time of plaque onset, or
expressed in the brain via adeno-associated virus–mediated (AAV–
mediated) delivery. Here we present in detail the features of antibody HAE-4 that facilitate its ability to decrease Aȕ deposition and
propose a likely mechanism of action.

Results
Characterization of the HAE series of apoE antibodies using recombinant human apoE. We used a direct ELISA to test whether the
HAE series of apoE antibodies binds to different recombinant
apoE isoforms (Figure 1, A–D). HAE-2 and HAE-3 recognized
all 3 isoforms of human apoE (Figure 1, B and C), whereas
HAE-4 had much higher affinity for apoE3 and apoE4 with

no appreciable binding to apoE2 (Figure 1D).
HAE-1 was apoE4-specific (Figure 1A). Using
surface plasmon resonance (SPR) (Figure 1,
E–G), the apparent KD values were determined
for HAE-1 (6.02 × 10 –8 M), HAE-2 (3.19 × 10 –10
M), and HAE-4 (1.98 × 10 –7 M) for their interaction with recombinant apoE4 (Table 1).
The KD value for HAE-3 was not determined
because it showed binding characteristics
similar to those of HAE-2 in ELISA (Figure 1,
B and C). Oddly, the maximum response units
for HAE-1 and HAE-4 as measured by SPR
were only 10% of the maximum value seen for
HAE-2, despite greater apoE4 capture levels
for experiments with HAE-1 and HAE-4. This
suggested the possibility that these 2 antibodies were recognizing a minor fraction of the
immobilized apoE, a hypothesis that was later
validated (see below).
Effects of intracerebroventricularly administered anti–apoE antibodies on Aȕ pathology
in APPPS1-21/APOE4 mice. apoE is present in
Aȕ-containing amyloid plaques in both human
AD as well as in mouse models of amyloidosis
(8, 9, 14). To test whether HAE antibodies are
able to decrease Aȕ pathology in APPPS1-21/APOE4 mice, we
directly infused the antibodies into the lateral ventricle of the mice
before plaque onset, starting at the age of 2 months. Antibodies
were infused continuously (0.3 ȝg/h) via an osmotic pump for 6
weeks and mice were assessed at the age of 3.5 months (females,
n = 10–11 per group). Infusions of PBS or a control mouse IgG2ab
into the mouse brain were included as negative controls, and anti–
Aȕ antibody HJ5.1 (15) was used as a positive control. Aȕ plaques
were stained using anti–Aȕ antibody HJ3.4 (Supplemental Figure 1A; supplemental material available online with this article;

Table 1. Apparent KD values of HAE-1, HAE-2, and HAE-4
calculated based on the SPR experiment
Antibody
HAE-1
HAE-2
HAE-4

jci.org

Volume 128

Ka (1/Ms)

Kd (1/s)

Apparent KD (M)

2.0E+04
6.6E+05
2.6E+04

1.2E-03
2.1E-04
5.2E-03

6.0E-08
3.2E-10
2.0E-07
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Figure 2. Effects of intraperitoneally administered anti–apoE antibodies on amyloid pathology in APPPS1-21/APOE4 mice. At the age of 2 months,
the mice were injected i.p. weekly with 50 mg/kg antibodies (all female, n = 10–13/group). The mice were sacrificed at the age of 3.5 months and the Aȕ
pathology in the brain was assessed using histology and biochemical approaches. (A) Representative Aȕ staining using HJ3.4 (left panel) and representative X-34 staining for fibrillar plaques (right panel). Scale bar = 1 mm. (B) Quantification of HJ3.4 staining. (C) Quantification of X-34 staining. (D) Aȕ40
and (E) Aȕ42 was measured by ELISA in insoluble fractions of tissue lysates (Guan = Guanidine) by ELISA. One-way ANOVA followed by Tukey’s t test was
performed to compare different groups shown in B–E. Data are mean ± SEM. *P < 0.05, **P < 0.01.

https://doi.org/10.1172/JCI96429DS1), and fibrillar plaques were
stained using Thioflavin S (Supplemental Figure 1B). The cortical tissue was extracted sequentially in PBS (soluble), 1% Triton
X-100, and 5 M guanidine HCl (insoluble). Levels of insoluble
Aȕ40 and Aȕ42 were determined by ELISA (Supplemental Figure 1,
C and D). HJ5.1 (anti-Aȕ) and the anti–apoE antibodies HAE-1 and
HAE-4 significantly reduced Aȕ plaque load compared with a control mouse IgG2ab (Supplemental Figure 1A). HAE-4 also significantly reduced Aȕ plaque load compared with PBS (Supplemental
Figure 1A). Some of the antibodies tended to decrease fibrillar Aȕ
and insoluble Aȕ40 and Aȕ42, but the effects were not statistically
significant (Supplemental Figure 1, B–D).
Effects of peripheral administration of anti–apoE antibodies on
Aȕ pathology in APPPS1-21/APOE4 mice. Because i.c.v.-administered HAE-1 and HAE-4 significantly reduced the Aȕ plaque
2146
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load in APPPS1-21/APOE4 mice, we tested whether peripheral
administration of HAE-1 and HAE-4 could impact Aȕ pathology
in these mice. Beginning at the age of 2 months, APPPS1-21/
APOE4 mice (females, n = 10–13 per group) were treated weekly
with i.p. injections (50 mg/kg body weight) of antibodies until
3.5 months of age. A group of untreated mice were harvested at
2 months to determine baseline Aȕ pathology. As determined
by Aȕ immunostaining, HAE-4 significantly reduced Aȕ plaque
load compared with the mouse IgG2ab control (Figure 2, A and
B). X-34 staining suggested that HAE-4 also reduced fibrillar
plaque load, but the effect was not significant (Figure 2, A and
C). However, HAE-4 significantly reduced insoluble Aȕ40 (Figure 2D) and Aȕ42 (Figure 2E) in the guanidine fraction of the
cerebral cortex, as compared with both the PBS- and IgG2abtreated control groups at the same age. There were no signifi-
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Figure 3. Binding profile of HAE-1, HAE-2, and HAE-4 with lipidated apoE. (A and B) Antibody binding to mouse plasma from EKO, APOE2, APOE3, and
APOE4 mice was coated onto the plates. Titrations of chi–HAE-2 and chi–HAE-4 were incubated and antibody that was captured was detected with
HRP-goat anti–human IgG antibody. (C and D) HAE-2 or HAE-4 was immobilized on the plate followed by the addition of plasma from mice with different
genotypes. apoE, captured from the plasma, was detected with HRP-goat polyclonal anti-apoE. (E) Plasma inhibition of anti-apoE binding to immobilized
recombinant apoE4. HAE-1 (50 nM), HAE-2 (4 nM), and HAE-4 (50 nM) were preincubated with serially diluted plasma from APOE4-KI mice and then
added to plates coated with recombinant apoE4. The HAE antibodies bound to the plates were detected with HRP-goat anti–mouse IgG antibodies. (F)
Plasma antibody concentrations of HAE-4 or control IgG following i.p. injection into APOE4-KI or EKO mice. HAE-4 was dosed at 2 mg/kg, 10 mg/kg, and
50 mg/kg and plasma samples were collected by submandibular puncture. Control murine IgG2a (msIgG2a) was anti-Her2 and dosed at 10 mg/kg. Quantification of dosed antibodies in plasma was by antigen-capture ELISA using coated recombinant apoE4 to detect HAE-4, with recombinant Her2 used to
detect the control IgG.

cant changes in levels of brain apoE, plasma apoE, or plasma Aȕ
after HAE-1 or HAE-4 treatment relative to the control groups
at the same age (Supplemental Figure 2). A possible reason that
the i.p. injection of 50 mg/kg HAE-4 had a somewhat greater
effect on reducing Aȕ levels than the results obtained with
chronic i.c.v. infusion (Supplemental Figure 1) is that the concentration of HAE-4 in the brain after 6 weeks of treatment was
significantly higher with the i.p. injection paradigm (6.37 ± 2.05
ng/100 mg tissue, n = 13) than the i.c.v. infusion paradigm (2.16
± 0.7 ng/100 mg tissue, n = 9) (P = 0.001). Unlike HAE-4, HAE1 had no significant effect on lowering Aȕ levels. This may be
due to the fact that HAE-1 is an IgG1 antibody whereas HAE4 is an IgG2ab antibody. Mouse IgG1 antibodies bind poorly to
FcȖR1 receptors (16). In a separate experiment performed under
the same conditions, HAE-3 did not change the Aȕ plaque load,
fibrillar plaque load, or insoluble Aȕ in the brain compared with
PBS-treated mice (Supplemental Figure 3). This is likely due
to the very short half-life of HAE-3 in the blood following i.p.
injection (see below). In another cohort of APPPS1-21/APOE4

animals, we performed a dose-response study with HAE-4. At
2 months of age, the mice (mixed sexual phenotype, n = 17–18/
group) received weekly i.p. injections of control IgG2ab (50 mg/
kg), anti–Aȕ antibody HJ3.4, which recognizes amyloid plaques
(50 mg/kg), or HAE-4 (2, 10, and 50 mg/kg) for 2.5 months
prior to sacrifice. There was a significant dose-dependent effect
of HAE-4 on reducing insoluble Aȕ40 and Aȕ42 levels in the brain
(Supplemental Figure 4).
Binding profile of HAE antibodies to lipidated apoE. Given that
the antibodies were chronically injected into the peripheral compartment at high levels, we were somewhat surprised that HAE-1
and HAE-4 did not affect levels of plasma apoE or brain apoE,
as apoE is abundant in both locations. This prompted us to ask
whether some of the anti–apoE antibodies bound differentially
to lipidated apoE versus other forms of the protein. In order to
assess binding to lipidated apoE, we characterized the binding of
HAE antibodies to plasma-derived apoE, the majority of which is
lipidated. Plasma that contained intact plasma lipoproteins from
apoE-KO (EKO), APOE2-, APOE3-, and APOE4-KI mice was
jci.org
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Figure 4. HAE-1 and HAE-4 staining of amyloid plaques in unfixed mouse brain sections and specificity for heat-induced aggregates of apoE4. (A)
Unfixed frozen brain sections from APPPS1-21/APOE4 or APPPS1-21/EKO mice were stained with anti–Aȕ antibody HJ3.4 and anti–apoE antibodies HAE-1
and HAE-4. Scale bar = 400 ȝm. (B) Binding of HAE-1, HAE-2, and HAE-4 to untreated recombinant apoE4 (untreated) or apoE4 that had been incubated at
40°C for 24 hours (40°C). (C) Incubation of apoE4 at 40°C for 24 hours results in the formation of aggregates recovered in the pellet fraction following ultracentrifugation at 186,000 g for 1 hour. Lane 1, untreated apoE4. Lane 2, apoE4 that had been incubated at 40°C for 24 hours. Supernatant (S) and pellet (P)
from ultracentrifugation were resolved on SDS-PAGE and stained by Coomassie blue. (D) Binding of HAE-4 to different preparations of apoE4 immobilized
at the same concentration (0.5 ȝg/ml) on the ELISA plate. Sup of untreated: supernatant fraction of untreated apoE4 from ultracentrifugation. Sup/Pel
of 24 hours 40°C: supernatant/pellet fraction of apoE4 incubated at 40°C for 24 hours. (E) Binding of HAE-4 to untreated apoE4 and apoE4 that had been
incubated at 40°C before and after denaturation by 1% SDS or 4 M guanidine HCl.

coated on ELISA plates. Chimeric anti–apoE antibodies HAE-2
(chi–HAE-2) and HAE-4 (chi–HAE-4), which consist of mouse
variable regions fused to human constant regions, were added
to the plasma-coated plates, and bound chi–HAE-2 or chi–HAE-4
was detected using anti–human IgG. Chi–HAE-2 bound to plasma
containing lipidated apoE2, apoE3, and apoE4 (Figure 3A). In
contrast, chi–HAE-4 did not bind strongly to plasma containing
lipidated apoE2, apoE3, and apoE4 (Figure 3B). To rule out that
the coating of apoE from plasma onto plates alters its conformation and its possible detection by the apoE antibodies, we then
performed a sandwich ELISA by coating HAE-2 or HAE-4 onto
the plates, incubating with plasma from EKO, APOE2, APOE3,
and APOE4 mice, and detecting with a polyclonal anti–apoE antibody. Lipidated apoE2, apoE3, and apoE4 in the respective plasma
samples was captured by HAE-2 (Figure 3C) but not HAE-4 (Figure 3D). Next, we tested the ability of plasma to inhibit the binding of HAE-1, HAE-2, and HAE-4 to immobilized recombinant
nonlipidated apoE4. Antibodies were preincubated with serially
diluted plasma from APOE4 mice and subsequently added to the
recombinant apoE4-coated plate. The results showed that plasma
inhibited the binding of HAE-2 to immobilized apoE4, suggesting
that HAE-2 bound both lipidated and nonlipidated forms of apoE.
2148
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In contrast, plasma did not inhibit the binding of HAE-1 or HAE4, suggesting that these antibodies do not bind lipidated forms of
apoE (Figure 3E).
The difference in ability to recognize plasma-derived apoE
was further supported by the pharmacokinetic profiles of HAE-1,
HAE-2, HAE-3, and HAE-4. Following i.p. injection (10 mg/kg)
into APOE4 mice, HAE-2 and HAE-3 were rapidly cleared from
plasma within 4 hours (Supplemental Figure 5), whereas HAE-4
was present in the plasma 14 days after injection at levels similar
to a control mouse IgG2a antibody (Figure 3F). The likely targetmediated clearance observed with HAE-2 and HAE-3 suggests that
these antibodies bind to plasma-derived lipidated apoE, which is
abundant in the plasma (~50 ȝg/ml), whereas HAE-1 and HAE-4
do not. HAE-1 and HAE-4 appear to be selective for nonlipidated
apoE, which is low or absent in plasma.
Binding of HAE-4 to plaque and aggregated apoE. Using unfixed
frozen brain sections from APPPS1-21/APOE4 or APPPS1-21/
EKO mice, we evaluated whether HAE-1 and HAE-4 could recognize apoE in the brain (Figure 4A). The presence of Aȕ plaques
was confirmed with Aȕ immunostaining using anti–Aȕ antibody
HJ3.4 on sections from the same brain. Given the lower total signal seen by SPR for HAE-1 and HAE-4 compared with HAE-2 (Fig-
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Figure 5. Binding of HAE-1, HAE-4, and control antibody to human apoE4 in the brains of living mice. (A) Control IgG2ab (n = 7), HAE-1 (n = 5), and HAE-4
(n = 6) conjugated with Alexa 594 were applied directly onto the surface of the brain in living APPPS1-21/APOE4 mice that were 6 months of age, and
antibody localization was observed using 2-photon microscopy. Amyloid was labeled using methoxy-X04. The signal from Alexa 594 and methoxy-X04 was
merged (MERGE) to show the colocalization of antibodies and plaques. (B) Control human IgG (n = 2) or chi–HAE-4 at 50 mg/kg body weight was injected
i.p. in 1 dose (0 hour, n = 3) or 2 doses (0 and 48 hour, n = 3). APPPS1-21/APOE4 mice were sacrificed 48 hours after final injection. The antibodies in the
brain were detected by biotinylated rabbit anti–human IgG followed by DAB. Left panel, bar = 1 mm. Right panel, high-power image of the indicated areas
shown in the left panel; bar = 300 ȝm.

ure 1, E–G), we hypothesized that HAE-1 and HAE-4 bound to a
less-abundant subspecies of the recombinant apoE4 that had been
immobilized on the sensor chip. To assess whether HAE-4 binds
to aggregated forms of apoE, we compared the binding of HAE-1,
HAE-2, or HAE-4 to untreated apoE4 or apoE4 preincubated
overnight at 40°C. HAE-2 bound to both forms of apoE similarly,
whereas the binding of HAE-1 and HAE-4 to heat-treated apoE was
dramatically enhanced (Figure 4B). HAE-1 preferentially binds to
nonlipidated apoE4 and HAE-4 preferentially binds to nonlipidated apoE3 and apoE4. The binding preferences of HAE-1 to apoE4
and HAE-4 to apoE3 and apoE4 are retained with heat treatment
(Supplemental Figure 6). In other words, HAE-1 and HAE-4 show
strong preferential binding to aggregated apoE4 (HAE-1) or to
apoE3 and apoE4 (HAE-4). Heat treatment of apoE resulted in the
formation of apoE aggregates that could be recovered in the pellet fraction following ultracentrifugation at 186,000 g for 1 hour
(Figure 4C). See complete unedited blots in the supplemental
material. Compared with apoE recovered from the supernatant
fraction, HAE-4 was able to bind apoE from the pellet fraction
much more readily (Figure 4D). This suggests that HAE-4 preferentially recognizes aggregated apoE generated by heat treatment.
Solubilization of the apoE aggregates using 1% SDS or 4 M guanidine eliminated the preference of HAE-4 for heat-induced apoE
aggregates (Figure 4E). In summary, these data suggest that HAE4 preferentially binds to aggregated forms of apoE, which may be
the predominant form of apoE found in the plaques of APPPS1-21
mouse and human brain sections.

Binding of HAE-4 to brain apoE in vivo. Next, we tested whether
HAE-1 and HAE-4 could bind to apoE in the brains of living mice. A
mouse IgG2ab (control), HAE-1, and HAE-4 were conjugated with
Alexa 594 and applied to the brain surface (40 ȝl of 1 mg/ml) of
6-month-old APPPS1-21/APOE4 mice. Antibody localization was
monitored through a cranial window using 2-photon microscopy
(Figure 5A). HAE-1 and HAE-4 were found to localize to amyloid
plaques. To test whether peripherally administered apoE antibodies could enter the brain and bind to apoE in plaques, chi–HAE-4
or control human IgG were i.p. injected (50 mg/kg) for 1 or 2 doses
into 5- to 6-month-old APPPS1-21/APOE4 mice. Two days after
the final injection, chi–HAE-4 was detected bound to plaques in the
dosed mice (Figure 5B). This indicated that chi–HAE-4 was able to
enter the brain and bind to apoE in the Aȕ plaques in living animals.
The effects of HAE-1 and HAE-4 on microglial activation and
Aȕ deposition: requirement of a microglial response. To determine
whether HAE-1 and HAE-4 antibodies can increase activated
microglia or infiltrating monocytes, we quantified CD45+ cells relative to the amount of fibrillar plaques after short-term treatment
of HAE-1 and HAE-4 antibodies (4 doses by i.p. injection every 3
days) in 4-month-old APPPS1-21/APOE4 mice that already had
existing plaques (Figure 6A and Supplemental Figure 7). After
acute passive immunization, HAE-1 had no effect on the amount
of CD45+ cells, whereas HAE-4 significantly increased the CD45+
cells compared with the controls (Figure 6A). Interestingly, there
was no increase in the number of Iba-1+ cells around plaques following HAE-4 treatment (1.02 × 10–4 ± 8.63 × 10–6 cells/ȝm3 for
jci.org
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Figure 6. Reduction of plaques by HAE-1 and HAE-4 requires
effector function. (A) At the age of 4 months, the APPPS1-21/
APOE4 mice received 4 i.p. injections of 50 mg/kg of antibodies every 3 days. The mice were sacrificed 24 hours after the
final injection and the fibrillar plaques were stained with X-34
and the activated microglia was stained with CD45. The ratio
of percentage of area covered by CD45 staining/percentage of
area covered by X-34 staining was quantified (equal numbers
of male and female mice, n = 8–9/group). (B–E) APPPS1-21/
APOE4 mice were injected at day P0 with AAV 2/8 into the
lateral ventricle (equal numbers of male and female mice,
n = 17–25/group). AAV 2/8 is able to express and secrete
full-length HAE-1 and HAE-4 antibodies as well as the same
constructs with a D265A mutation in the Fc domain (HAE-1ǻ
and HAE-4ǻ). At the age of 3.5 months, the Aȕ plaques (B)
were stained with antibody HJ3.4, the fibrillar plaques were
stained with X-34 (C), and the insoluble Aȕ42 (D) and Aȕ40
(E) were measured by ELISA. One-way ANOVA followed by
Tukey’s t test was performed to compare different groups
shown in A–E. Data are mean ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.

control, n = 7 vs. 1.29 × 10 –4 ± 2.09 × 10 –5 cells/ȝm3 for HAE-4, n =
7) suggesting that together with the CD45 data the total number
of either microglia or infiltrating monocytes around plaques was
not increased, but the cells present were in a more activated state.
Although HAE-1 and HAE-4 can bind to apoE in plaques, antibody-driven plaque reduction may be dependent upon microglial
activation. In order to assess whether microglia are required for
an HAE-1– or HAE-4–dependent decrease in Aȕ accumulation,
we used AAV serotype 2/8 to drive the expression and secretion
of full-length HAE-1 and HAE-4 antibodies with and without a
D265A mutation in the Fc domain. The D265A mutation removes
virtually all binding to FcȖ receptors and prevents these antibodies from effectively activating microglia (17). AAV vectors expressing these antibodies (all with an IgG2ab Fc domain or a control
IgG2ab antibody) were injected into APPPS1-21/APOE4 mice at
P0. Mice were then sacrificed at 3.5 months of age and assessed.
We measured the levels of HAE-1 and HAE-4 antibodies with
and without the D265 mutation in the cortex and found that they
were all expressed at similar levels with no statistical differences
among the different antibodies (Supplemental Figure 8). The
levels of HAE-1 and HAE-4 were much higher in the cortex with
AAV-mediated expression (over 20 ng/100 mg tissue) in the mice
at 3.5 months of age than they were after 6 weeks of i.p. injections
(~6 ng/100 mg tissue). Following AAV-mediated expression of
HAE-1 or HAE-4 in APPPS1-21/APOE4 mice, there was a strong
and significant reduction of Aȕ immunostaining, fibrillar Aȕ, and
insoluble Aȕ40 and Aȕ42 as compared with control antibody–treated mice (Figure 6, B–E). In contrast, the AAVs expressing HAE-1 or
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HAE-4 with a D265A mutation had no effect on Aȕ immunostaining, fibrillar Aȕ, and insoluble Aȕ40 or Aȕ42 relative to the control
antibody (Figure 6, B–E). This strongly suggests that anti–apoE
antibodies that bind to apoE in Aȕ plaques decrease Aȕ accumulation through an FcȖR-mediated mechanism.

Discussion
In the present study, we report that both i.c.v. and i.p. administration of the anti–human apoE antibody HAE-4 (specific for apoE3
and apoE4) into APP transgenic mice expressing human apoE4
significantly reduced Aȕ plaque load and Aȕ accumulation in the
brain. HAE-4 preferentially binds to nonlipidated forms of apoE as
compared with lipidated apoE, which is the major form of apoE in
vivo. When monomeric and aggregated forms of apoE were compared, HAE-4 preferentially bound to apoE aggregates. HAE-4
bound to apoE in amyloid plaques after direct application to the
brain surface or after peripheral administration into living animals. Importantly, HAE-4 did not significantly alter the levels of
total apoE in the brain or plasma, and both HAE-1 and HAE-4 were
able to reduce plaque accumulation by direct central administration or expression via AAV. This effect appears to require microglial activation, as the corresponding antibodies with mutations in
the Fc effector domain of the antibodies that ablate FcȖ receptor
binding are not effective in plaque clearance. Overall, these findings demonstrate that certain anti–apoE antibodies selective for
nonlipidated, aggregated apoE, such as HAE-1 and HAE-4, can
preferentially bind to apoE in plaques and have very similar effects
to anti–Aȕ antibodies that also bind to and decrease Aȕ accumula-
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tion via a microglial-mediated clearance mechanism (18, 19). Further studies will be required to determine potential advantages
and disadvantages to this approach versus the use of anti–Aȕ antibodies as a treatment modality.
Although apoE has been established as the strongest genetic
factor for LOAD for more than 20 years, the mechanism(s) by
which apoE modifies AD pathogenesis is still not entirely clear.
However, a large body of literature shows that apoE affects AD
at least in part through exacerbating Aȕ aggregation and reducing its clearance (7, 20, 21). The effects of apoE isoform, level, or
lipidation status on Aȕ pathology have been extensively studied
in vitro and in vivo (7, 21). Whether increasing or decreasing of
apoE function or expression is beneficial for reducing Aȕ pathology has long been debated. Overexpression of apoE2 using viral
vectors reduces Aȕ pathology, whereas overexpression of apoE4
increases Aȕ pathology in APP transgenic mice (22–25). Increasing apoE4 expression prior to but not after Aȕ deposition enhances plaque burden (26). Genetic removal of endogenous murine
apoE or reduction of apoE with antisense oligonucleotides prior
to the onset of Aȕ deposition decreases Aȕ plaque load and fibrillar plaques in APP transgenic mice (27–29). Lowering apoE levels
after Aȕ deposition had started had no effect on Aȕ levels (29). APP
mice that express 1 copy of human apoE have markedly less Aȕ
pathology as compared with those expressing 2 copies of the same
apoE isoform (30, 31). Blocking the interaction between apoE and
Aȕ using Aȕ12-28p suppresses Aȕ plaque deposition in APP transgenic mice (32). Taken together, only the overexpression of the
apoE2 isoform appears beneficial, at least with respect to reducing
Aȕ accumulation. Based on the effects we describe, the ability to
target specific pools of apoE might be an ideal therapeutic strategy
to address the more than 60% of the patients with LOAD who are
apoE4 carriers. Importantly, this approach of specifically targeting
apoE in plaques allows for a direct antibody-mediated decrease in
Aȕ accumulation, in contrast to the alternate approach of simply
lowering apoE levels. Whether anti–apoE antibodies such as HAE4 will clear existing apoE-containing plaques will need to be tested
in future studies.
In previous studies, we found that anti–mouse apoE antibody
HJ6.3 reduced Aȕ plaque load in APPPS1 mice expressing murine
apoE (10, 11). In those studies, we were not able to determine
the mechanism whereby anti-apoE modulated plaque pathology.
To better explore this issue, as well as to develop antibodies that
bind to human apoE, we generated a series of anti–human apoE
antibodies and assessed their efficacy and mechanism of action
in mice that develop Aȕ deposition and express human apoE4.
We focused most of these studies on antibody HAE-4, as it was
most effective at reducing plaques when given peripherally. We
first analyzed the apoE levels in the treated animals. Similar to the
findings in our previous study using anti–mouse apoE antibody
HJ6.3 (10, 11), peripheral administration of HAE-4 did not change
the level of plasma apoE or the level of total brain apoE in the tissue lysates. Therefore, the effects of HAE-4 on Aȕ plaques were
not mediated simply by lowering total apoE levels. It was previously reported that a plaque-specific Aȕ antibody (mE8) that targets only pyro-glutamated Aȕ, a small proportion of Aȕ in amyloid
plaques, was able to localize to Aȕ plaques and remove them by
triggering microglia-mediated phagocytosis (19). In the present

study, we found that HAE-4 is able to bind to apoE in amyloid
plaques, both on unfixed brain sections and in the brain of living
APPPS1-21/APOE4 mice following central or peripheral injection.
Further, we found that the ability of HAE-4 to decrease plaque
accumulation was dependent on microglial activation. This suggests that the key features of this antibody’s ability to decrease Aȕ
plaques are its selectivity toward binding a conformation of apoE
in amyloid plaques, specifically apoE aggregates, and its ability to
direct microglial-driven apoE-amyloid phagocytosis.
To better understand whether the antibody most effective at
decreasing plaques was binding to a particular form of apoE that
was selectively present in plaques and not normally found in brain
or blood, we assessed the binding affinity of HAE-4 to lipidated
verus nonlipidated apoE as well as monomeric versus aggregated
apoE. We found that HAE-4 preferentially interacts with a nonlipidated form of apoE as compared with lipidated forms that would
be present in plasma, cerebrospinal fluid, or the extracellular space
of the brain. This is the first report to our knowledge that suggests
that targeting a specific conformational form of apoE reduces Aȕ
pathology in APP transgenic mice. Given that nonlipidated apoE
is only a small percentage of total apoE in vivo (33), targeting this
pool of apoE may underlie the lack of effect on apoE levels or lipid
metabolism. Reduced binding to lipidated apoE contributes to the
much longer plasma half-life of HAE-4 as compared with HAE-2
and HAE-3, which strongly bind lipidated apoE (Figure 3F, Supplemental Figure 5). A longer half-life greatly increases both peripheral and brain exposure of the antibody and enables increased
plaque decoration.
Previous work has shown that decreasing Aȕ pathology by
enhancing apoE lipidation via ATP-binding cassette transporter
A1 (ABCA1) has beneficial effects (34–36), and that decreasing
apoE lipidation increases Aȕ pathology (37). It is possible that
poorly lipidated apoE adopts a conformation more prone to aggregation and thus promotes Aȕ aggregation. In the present study, we
demonstrated that a potent, plaque-reducing antibody may recognize this form of aggregated apoE, which resides in Aȕ plaques in
APPPS1-21/APOE4 mice. In the future, the frequency and abundance of HAE-4 immunoreactivity apoE in the brain of patients
with AD will need to be determined.
We found that the effects of 2 different anti–apoE antibodies
appear to require microglial-mediated Aȕ phagocytosis, because
versions of HAE-1 and HAE-4 lacking a functional Fc domain of
the antibody were not able to decrease Aȕ deposition. In addition, in APPPS1-21/APOE4 mice that already had plaques, HAE-4
acute administration substantially increased CD45+ cells around
plaques. A variety of anti–Aȕ antibodies have been studied for
their ability to decrease Aȕ plaques both in animal models and
in humans. The antibodies shown to have the greatest effects
on Aȕ deposition appear to work by binding certain Aȕ species
in plaques and then facilitating clearance via microglial phagocytosis (18, 19). The mechanism we demonstrate here for HAE-1
and HAE-4 appears similar, except that these antibodies bind to
an Aȕ-binding molecule (i.e., apoE) and not directly to Aȕ itself.
The effects we see with these antibodies appear similar to that
seen with Aȕ antibodies that lower plaques. Whether the CD45+
reactive cells are microglia or infiltrating monocytes and to what
extent FcR expressed by other cell types in the brain contribute
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to the process of decreasing Aȕ accumulation needs to be sorted
out in future studies. In addition to efficacy, it will be important
to determine whether anti–apoE antibodies with features such
as HAE-4 have any potential side effects. We were not able to
determine whether there was an increase in microhemorrhages
in the APPPS1-21/APOE4 mice following treatment with HAE-4,
as there was very little amyloid angiopathy in this mouse model.
Future studies addressing this issue may support the development
of anti–apoE antibodies for the treatment of AD.

Methods
Animals. APPPS1-21 mice on a C57BL/6J background (gift from
Mathias Jucker, Hertie Institute for Clinical Brain Research, Tubingen, Germany) coexpress human APP with a Swedish mutation
(KM670/671NL) and mutant PS1 with the L1669 mutation under the
control of a Thy1 promoter (13). APOE2-, APOE3-, and APOE4-knockin mice express APOE E2, E3, and E4 under control of the endogenous
mouse regulatory elements on a C57BL/6J background (38). EKO
mice were purchased from Taconic. APPPS1-21/APOE4 mice were
generated by breeding APPPS1-21 with APOE4 mice. The Aȕ plaque
pathology in APPPS1-21/APOE4 mice begins at the age of 2 months.
Generation of antibodies. The HAE antibodies were generated by
injecting recombinant apoE4 with complete Freund’s adjuvant into
mice. For an initial screening of antibodies, supernatants from hybridoma cells were added to 96-well plates coated with recombinant apoE4
and the HAE that bound to apoE4 was detected using anti–mouse IgG
HRP. The antibodies that performed well in the initial screening were
further characterized and selected for in vivo studies. For the in vivo
study, antibodies were generated from cultured hybridoma cells and
purified on a protein G column. All HAE antibodies utilized in vivo
contained similar amounts of endotoxin as compared with control
antibodies. All 4 anti–apoE antibodies studied are mouse IgGs. HAE-1
is an IgG1. HAE-2, HAE-3, and HAE-4 are IgG2ab subtypes.
apoE binding ELISAs. Recombinant apoE (Leinco Technologies)
was coated to half-area 96-well plates at 0.5 ȝg/ml in PBS overnight at
4°C (25 ȝl/well). After 3 washes with PBS, the wells were blocked with
1% BSA-PBS for 1 hour at room temperature with shaking at 500 rpm.
The blocked wells were washed once with PBS and subsequently loaded with HAE antibodies at serial concentrations (starting at 300 nM
with 3-fold dilutions thereafter). Bound HAE antibodies were detected
with HRP-labeled goat anti–mouse IgG (catalog 115-035-003, Jackson
ImmunoResearch Laboratories) and visualized with tetramethylbenzidine (TMB) substrate at OD450 (reaction stopped with 4N H2SO4) or
OD650 (reaction stopped with BioFX stop solution, Surmodics). For
experiments where apoE aggregation was first induced by heating,
recombinant apoE4 at a concentration of 1 mg/ml was first heated
at 40°C for 24 hours and then coated directly to ELISA plates at 0.5
ȝg/ml. To normalize the amount of apoE coated to the ELISA plates
from the supernatant and pellet fractions after heating and ultracentrifugation, the relative amounts of apoE were first assessed by
SDS-PAGE followed by a Coomassie blue stain. Heat-induced apoE4
aggregates were denatured in 1% SDS or 4 M guanidine-HCl at 95°C
for 10 minutes and then diluted to 0.5 ȝg/ml in PBS for coating onto
ELISA plates. After overnight incubation at 4°C, the wells were washed
3 times with PBS to remove any residual SDS or guanidine-HCl. ELISA
experiments with heated apoE used HAE antibodies starting at 100
nM with 5-fold dilutions thereafter.
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Surface plasmon resonance. Anti–biotin antibody (catalog 28920233,
GE Healthcare) was immobilized on the surface of a CM5 chip (GE
Healthcare) through amine coupling. The surface was activated by
injection of a mixture of EDC/NHS (1-ethyl-3-[3-dimethylaminopropyl]
carbodiimide hydrochloride/N-hydroxysuccinimide) (GE Healthcare).
Anti–biotin antibody was diluted in sodium acetate (pH 5.0 at 12.5 ȝg/
ml) and injected for 10 minutes at a flow rate of 5 ȝl/min, followed by
injection of ethanolamine (GE Healthcare). Recombinant apoE4 was
biotinylated using the EZ-Link Sulfo-NHS-LC-Biotin kit (ThermoFisher
Scientific). Biotinylated apoE4 was captured on the chip to reach 550
RU (HAE-1 and HAE-4) or 280 RU (HAE-2). A range of serially diluted
antibodies (1.2 nM–100 nM for HAE-2; 12 nM–1,000 nM for HAE-1 and
HAE-4) was injected at a flow rate of 30 ȝl/min, and sensorgrams were
fitted using the 1:1 Langmuir model.
Intracerebroventricular antibody administration and sample collection. At the age of 2 months, APPPS1-21/APOE4 mice underwent surgical implantation of a subcutaneous osmotic minipump (Alzet, model
2006) connected to a catheter into the left lateral cerebral ventricle
(Bregma –0.4 mm, 1.0 mm lateral to midline, 2.5 mm below the skull).
The apoE antibodies or control antibodies (2 mg/ml) were filled into
the osmotic minipump and continuously infused (i.c.v.) at the speed of
0.15 ȝl/h for 6 weeks. At the age of 3.5 months, the mice were perfused
with ice-cold PBS containing 0.3% heparin. The right hemibrain was
dissected and flash-frozen on dry ice for biochemistry assays. The left
hemibrain was fixed in 4% paraformaldehyde for histological analysis. Serial coronal sections at 50-ȝm thickness were collected from the
rostral to the caudal end of each brain hemisphere using a freezing
sliding microtome (Leica Biosystems).
Intraperitoneal antibody administration and sample collection. Twomonth-old female APPPS1-21/APOE4 mice were injected i.p. with a
weekly dose of 50 mg/kg body weight of control or HAE anti–apoE
antibodies for 7 doses. At the age of 3.5 months, the mice were perfused with ice-cold PBS containing 0.3% heparin. The right hemibrain
was dissected and flash-frozen on dry ice for biochemical assays for
Aȕ and apoE. The left hemibrain was fixed in 4% paraformaldehyde
for 48 hours for histological analysis of amyloid plaque load. The fixed
brains were sectioned by Multibrain Technology (NeuroScience Associates NSA Labs) at a 50-ȝm thickness. For the dose-response study of
HAE-4, another cohort of APPPS1-21/APOE4 mice received weekly
i.p. injections of HAE-4 (2 mg/kg, 5 mg/kg, and 10 mg/kg), anti–Aȕ
HJ3.4 (50 mg/kg), or IgG2ab (50 mg/kg). The cortices were extracted
sequentially in PBS and 5 M guanidine and the Aȕ40 and Aȕ42 in the
guanidine fraction was assessed using ELISA.
ELISA for tissue lysates. To extract Aȕ in different fractions, brain
cortices were sequentially homogenized with cold PBS, 1% Triton-X
100, and 5 M guanidine buffer in the presence of 1× protease inhibitor mixture (Roche). The levels of Aȕ40, Aȕ42, and apoE were measured
by sandwich ELISA. For Aȕ40 or Aȕ42, anti–Aȕ35–40 HJ2 (produced inhouse) or anti–Aȕ37–42 HJ7.4 (produced in-house) were used as capture
antibodies, and anti–Aȕ13–18 HJ5.1–biotin (produced in-house) was
used as a detecting antibody (39). For apoE ELISA, HJ6.2 (produced
in-house) (10) was used as the capture antibody and HJ6.1-biotin (produced in-house) (10) was used as the detecting antibody. Recombinant apoE4 was used as the standard for the apoE ELISA. For assessment of the concentration of rHAE-1, rHAE-1ǻ, rHAE-4, and rHAE-4ǻ
following expression via AAV2/8, recombinant apoE4 was coated on
96-well ELISA plates overnight at 4°C. After washing, individual puri-
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fied hybridoma-derived and purified HAE-1 or HAE-4 were added to
wells at different concentrations for a standard curve or the PBS-soluble fraction of mouse cortex was added to the wells. Following washing, the antibodies were detected with HRP-coupled anti–mouse IgG.
Immunohistochemistry for Aȕ pathology. Aȕ plaques were immunostained using biotinylated anti–Aȕ1–13 monoclonal antibody HJ3.4B
(produced in-house) (11). Fibrillar plaques were stained with 0.025%
Thioflavin S (Sigma-Aldrich) or 10 nM X-34. Quantitative analysis of
immunopositive staining was performed as previously described (39).
All quantitation of Aȕ and Thioflavin S staining was done by an investigator who was blind to both mouse genotype and treatment condition. Briefly, images of immunostained sections were exported with
an NDP viewer (Hamamatsu Photonics), converted to 8-bit grayscale
using ACDSee Pro 2 software (ACD Systems), thresholded to highlight
positive staining, and analyzed using ImageJ software (NIH). Three
sections per mouse (Bregma, –1.4 mm caudal to Bregma, and –2.0 mm
caudal to Bregma) were quantified (cortex dorsal to hippocampus) and
the average was used to represent each mouse.
Binding of HAE antibodies to lipidated apoE. Blood was collected
from the right atrium of 6-week-old, apoE-targeted replacement mice
or EKO mice and centrifuged in plasma collection tubes (containing
EDTA) at 14,000 g for 5 minutes. For the plasma-coat ELISA, plasma
was diluted 50-fold in PBS and coated to the bottom of half-well ELISA plates overnight at 4°C. Plates were washed with PBS and blocked
in 5% BSA-PBS for 2 hours. Antibodies were serially diluted 5-fold
(starting at 500 nM) in 5% BSA-PBS and incubated for 1 hour at room
temperature with shaking (500 rpm). Plates were next washed extensively in PBS and bound antibody was detected with an HRP-goat anti–
human secondary antibody (catalog 109-035-003, Jackson ImmunoResearch Laboratories). TMB was used as the chromogenic reagent
and reactions were stopped with BioFX stop solution. Plates were read
at OD650. Replicate assays were performed and data from 1 experiment in duplicate are shown. For the plasma-capturing experiment,
antibodies were coated at 5 ȝg/ml in half-well ELISA plates overnight
at 4°C. Plates were washed with PBS and blocked in 4% milk-PBS for
2 hours. Mouse plasma was serially diluted 2-fold (starting at 10×) in
5% BSA-PBS and incubated on the blocked plates for 3 hours at room
temperature and shaken at 500 rpm. Plates were next washed extensively in PBS and the captured apoE was detected with polyclonal
goat anti–apoE (catalog 178479, Millipore). Anti–goat HRP (catalog
705-035-147, Jackson ImmunoResearch Laboratories) and TMB were
used as the detection secondary antibody and chromogenic reagent,
respectively. Reactions were stopped with BioFX stop solution and
plates were read at OD650. Replicate assays were performed and data
from 1 experiment in duplicate are shown. For the plasma competition experiment, recombinant apoE4 was coated onto half-well plates
at 0.5 ȝg/ml overnight at 4°C. Plates were washed extensively with
PBS and blocked for 1 hour in 4% BSA-PBS. Antibodies were diluted
in 4% BSA-PBS at double concentrations of the final stock solution
and equal volume was added for preincubation with serially diluted
plasma (also at a 2-fold final concentration) for 1 hour and shaken at
500 rpm. Blocked plates were washed twice and the preincubated
antibody/plasma solutions were added to the blocked plates for 1 hour
at room temperature with shaking (500 rpm). Plates were next washed
extensively in PBS and the bound primary antibody was detected with
an HRP-goat anti–mouse secondary antibody (catalog 115-035-003,
Jackson ImmunoResearch Laboratories). TMB was used as the chro-

mogenic reagent and reactions were stopped with BioFX stop solution.
Plates were read at OD650. Replicate assays were performed and data
from 1 experiment in duplicate are shown.
Pharmacokinetics of HAE antibodies in mice. Murine HAE-4 and
control mouse Ig2a anti-HER2 were injected i.p. at 2 mg/kg, 10 mg/
kg, and 50 mg/kg, and plasma samples were collected by submandibular puncture at various time points. Assessment of plasma antibody
concentrations was performed using coated recombinant apoE4 (5
ȝg/ml) to capture dosed HAE-4, and recombinant Her2 protein (R&D)
(1 ȝg/ml) to capture the control antibody. Plates were blocked with 3%
BSA in TBS/0.1%Tween for 1 hour and washed 3 times before incubation with plasma samples at a 1:2500 dilution. Bound antibodies were
detected with HRP-anti–mouse IgG (catalog 115-035-003, Jackson
ImmunoResearch Laboratories). The standard curve range was 0.49–
1000 ng/ml and fit with a 4-parameter logistic function.
Binding of HAE-1 and HAE-4 to apoE in the unfixed brain tissue.
Brain tissue from APPPS1/APOE4 and APPPS1/EKO mice was sectioned at 20-ȝm thickness using a cryotome (ULTRApro 5000, Vibratome) and mounted on slides. The sections were stained with biotinylated HJ3.4, HAE-1, or HAE-4. The antibodies bound to the sections
were detected using an ABC kit (Vector Laboratories) followed by DAB
(Sigma-Aldrich).
Cranial window implantation, topical application of antibodies and
multiphoton imaging. APPPS1-21/APOE4 mice (5.5–7 months old)
were anesthetized under 1.5% isoflurane, and a 4-mm cranial window
was drilled in order to expose the cortex, as previously described (24).
After removing the dura matter, 40 ȝl of each antibody stock (1.0 mg/
ml), previously conjugated with Alexa 594 (Alexa Fluor 568 Antibody
Labeling Kit, ThermoFisher Scientific), was topically applied for 30
minutes. After 2 washes with sterile PBS, a glass coverslip was cemented on the skull in order to seal the window before imaging. Fluorescein dextran (70,000 Da; 12.5 mg/ml in sterile PBS; Invitrogen) was
also injected retroorbitally to provide a fluorescent angiogram. After
a first set of images was taken in order to detect the signal from each
antibody alone, methoxy-XO4 (5 mg/kg) was injected intravenously in
order to label amyloid plaques as well as cerebral amyloid angiopathy,
as previously described (40). In vivo multiphoton imaging was performed using an Olympus FluoView FV1000MPE multiphoton laserscanning system mounted on an Olympus BX61WI microscope and an
Olympus ×25 objective (numerical aperture = 1.05). A DeepSee Mai
Tai Ti: sapphire mode-locked laser (Mai Tai; Spectra-Physics) generated 2-photon excitation at 800 nm, and detectors containing 3 photomultiplier tubes (Hamamatsu) collected emitted light in the range
of 420–460 nm, 495–540 nm, and 575–630 nm. Mice were placed on
the microscope stage, heated using a heating pad, and feedback regulation was obtained from a rectal temperature probe (Harvard Apparatus). Z-series images (2 ȝm steps, depth of ~200 ȝm, 512 × 512 pixels)
were taken to cover a large surface of the window. The laser power was
measured and adjusted before each imaging and the settings of the
photomultiplier tubes were unchanged throughout the different imaging sessions and between all antibodies applied.
Binding of peripherally administered chi–HAE-4 to apoE in the brain.
Chi–HAE-4 and control human IgG were injected i.p. at 50 mg/kg into
4- to 6-month-old APPPS1-21/APOE4 mice for 1 (0 hour) or 2 (0 and
48 hours) doses and the mice were sacrificed 48 hours after the final
injection. The antibodies were detected using biotinylated rabbit anti–
human IgG (catalog ab97158, Abcam) followed by DAB.
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Acute injection of HAE antibodies and microglial activation staining.
APPPS1-21/APOE4 mice received 4 doses of antibodies every 3 days
at the age of 4 months. Each dose was 50 mg/kg (administered i.p.).
The mice were sacrificed 24 hours after final injection. The fibrillar
plaques were stained using X-34. Activated microglia were immunostained using rat–anti CD45 (catalog MCA1388, BioRad) followed by
biotinylated goat anti–rat IgG secondary antibody (catalog A10517,
Life Technologies). Iba-1+ cells were detected using rabbit anti–Iba-1
(catalog 019-19741, Wako) followed by donkey anti–rabbit IgG Alexa
Fluor 647 (catalog A-31573, ThermoFisher Scientific). For quantification, 3 Z-stack images were captured per animal on the Nikon A1R+
confocal microscope using ×20 objective at 1024 × 1024 pixel resolution with a Z-step size of 1.1 ȝm at 32-ȝm thickness. These images were then processed using Imaris (Bitplane). The coordinates of
X-34+ plaques and Iba-1+ microglia were determined using the Spots
function and imported into Matlab (Mathworks). An automated script
was used to determine the microglial density around plaque surfaces,
and the number of microglia within a 30 ȝm radius was calculated.
Preparation and injection of AAV2/8 vectors expressing control antibody and HAE antibodies. The variable regions of heavy and light chain
cDNA sequences of control IgG, HAE-1, and HAE-4 were cloned from
hybridoma cells. The single open reading frame (ORF) of the heavy
chain, Furin cleavage site, P2A, and the light chain was assembled
by polymerase chain reaction. All antibody subtypes were switched
to mouse IgG2ab. The assembled single ORF was inserted into AAVexpressing vector (serotype 2) with a chicken ȕ actin promoter. The
D265A mutation on the CH2 region was generated by QuikChange
(Agilent Technologies) site-directed mutagenesis. AAV vectors were
prepared at Hope Center Viral Vector Core with serotype 8 helper
vectors. On P0, APPPS1-21/APOE4 mice (mixed sexual phenotype,
n = 17–25/group) received a bilateral i.c.v. injection of 2 ȝl AAV vector (1.0 × 1013 vg/ml). The mice were sacrificed at 3.5 months of age.
After perfusion with PBS, one brain hemisphere was immersion fixed
in 4% paraformaldehyde for further histological analysis and the other
hemisphere was dissected for further biochemical analysis. For histology, the brains were sectioned at 50 ȝm on a freezing sliding microtome. The Aȕ plaques were stained with anti–Aȕ HJ3.4 and the fibrillar plaques were stained using X-34. The cortices were sequentially
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extracted using PBS and 5 M guanidine, and Aȕ40 and Aȕ42 were measured by ELISA. The concentration of antibodies in the PBS fraction
was also measured by ELISA.
Statistics. Two-tailed Student’s t test was used to determine
whether there were significant differences between 2 groups unless
otherwise specified. One-way ANOVA was used to compare differences among 3 or more groups, followed by Tukey’s t test unless otherwise specified. Data in all the figures are mean ± SEM unless otherwise
specified. P < 0.05 was considered significant.
Study approval. All animal experimental protocols were approved
by the Animal Studies Committee at Washington University.
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